Mustang Bio, Inc. (MBIO): Price and Financial Metrics
MBIO Price/Volume Stats
Current price | $0.17 | 52-week high | $1.53 |
Prev. close | $0.17 | 52-week low | $0.13 |
Day low | $0.17 | Volume | 912,900 |
Day high | $0.17 | Avg. volume | 8,286,908 |
50-day MA | $0.23 | Dividend yield | N/A |
200-day MA | $0.37 | Market Cap | 8.02M |
MBIO Stock Price Chart Interactive Chart >
Mustang Bio, Inc. (MBIO) Company Bio
Mustang Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products based on the chimeric antigen receptor engineered T cell technology. Its lead programs include MB-101 for the treatment of brain cancer that is in Phase I trials; and MB-102, a therapeutic agent in acute myeloid leukemia, which is in Phase I trials. The company was founded in 2015 and is based in New York, New York. Mustang Bio Inc. is a subsidiary of Fortress Biotech, Inc.
MBIO Price Returns
1-mo | -18.23% |
3-mo | -23.42% |
6-mo | -70.19% |
1-year | -85.95% |
3-year | -99.39% |
5-year | -99.70% |
YTD | -87.41% |
2023 | -77.21% |
2022 | -76.21% |
2021 | -56.14% |
2020 | -7.23% |
2019 | 38.78% |
Continue Researching MBIO
Want to see what other sources are saying about Mustang Bio Inc's financials and stock price? Try the links below:Mustang Bio Inc (MBIO) Stock Price | Nasdaq
Mustang Bio Inc (MBIO) Stock Quote, History and News - Yahoo Finance
Mustang Bio Inc (MBIO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...